Worse still, first-line-medicines such as sorafenib can only extend the overall survival of patients for another 3 months, and the response rate of the emerging programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitor is lower than 20% in HCC patients (8, 9). The gene discussed is CD274; the disease is hepatocellular carcinoma.